Paradoxical upregulation of glutamatergic presynaptic boutons during mild cognitive impairment.
Synaptic integrity is now recognized as a central component of Alzheimer's disease. Surprisingly, however, the structural status of glutamatergic synapses in Alzheimer's disease is unclear, despite the fact that glutamate is the major excitatory transmitter of the CNS and has key roles in excitotoxicity and long-term potentiation. The identification of specific markers of glutamatergic neurons now allows an assessment of the structural involvement of the glutamatergic system across progressive stages of the Alzheimer's pathology, an opportunity not afforded by previously used neurochemical approaches. Glutamatergic presynaptic bouton density and dystrophic neurite abundance were quantified in midfrontal gyrus brain tissue from subjects with no cognitive impairment, mild cognitive impairment, or mild- or severe-stage Alzheimer's disease. Our study demonstrates a striking pathology-dependent pattern of glutamatergic synaptic remodeling with disease progression. Subjects with mild cognitive impairment display a paradoxical elevation in glutamatergic presynaptic bouton density, a situation akin to that observed in the cholinergic system, which then depletes and drops with disease progression. This pattern of synaptic remodeling mirrors our previous findings in transgenic animal models and is of major relevance to current transmitter-based therapeutics.
Bell
Karen F S
KF
Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada H3G 1Y6.
Bennett
David A
DA
Cuello
A Claudio
AC
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000150:complications / Q000209:etiology; D016229:Amyloid beta-Peptides; D000704:Analysis of Variance; D003072:Cognition Disorders / Q000473:pathology* / Q000503:physiopathology*; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D018698:Glutamic Acid / Q000378:metabolism*; D006801:Humans; D007091:Image Processing, Computer-Assisted / Q000379:methods; D008297:Male; D009474:Neurons / Q000473:pathology / Q000648:ultrastructure*; D009483:Neuropsychological Tests; D058225:Plaque, Amyloid / Q000378:metabolism; D017397:Prefrontal Cortex / Q000166:cytology; D017729:Presynaptic Terminals / Q000378:metabolism*; D012720:Severity of Illness Index; D015854:Up-Regulation
D016229:Amyloid beta-Peptides; D018698:Glutamic Acid